AMAG Pharmaceuticals, Inc.NASDAQ
Advanced Chart
  • Jun. 29, 2015, 2:33 PM
    • AMAG Pharmaceuticals (AMAG -2.9%) acquires Cord Blood Registry (CBR), the world's largest stem cell collection and storage firm, for $700M. CBR houses over 600K umbilical cord blood and tissue stem cell units representing over 50% of the privately stored cord units in the U.S.
    • In 2014, CBR generated ~$126M in revenues and $45M in non-GAAP EBITDA. 2015's top line is projected to be slightly above $126M. Expense synergies should be ~$15M per year.
    • The deal, expected to close in Q3, is being funded with debt.
    | Jun. 29, 2015, 2:33 PM | 2 Comments
  • Sep. 29, 2014, 4:27 PM
    • AMAG Pharmaceuticals (AMAG +28.2%) acquires privately-held Missouri-based Lumara Health for $675M in a cash-and-stock transaction. The deal consists of $600M in cash, $75M in stock and up to $350M in sales-related milestones.
    • Lumara focuses on women's health. It's lead product is the Orphan Drug Makena (hydroxyprogesterone caproate injection) indicated to reduce the risk of preterm birth in women who are pregnant with one baby and who have delivered one preterm baby spontaneously in the past.
    • Also, Lumara divests its portfolio of OTC products to Perrigo for $82M.
    | Sep. 29, 2014, 4:27 PM
  • Nov. 17, 2011, 8:42 AM

    AMAG Pharmaceuticals (AMAG) +4.7% premarket after announcing it has hired Jefferies as a strategic advisor to "explore all opportunities to enhance stockholder value," including a "potential sale of the company."

    | Nov. 17, 2011, 8:42 AM
  • Nov. 4, 2011, 11:36 AM

    AMAG Pharmaceuticals (AMAG +16.3%) shares rally after announcing a Q3 earnings beat, the resignation of its CEO, plans to cut a quarter of its employees, and a review of strategic options. “We’re evaluating all strategic alternatives available," interim CEO Frank Thomas said on a conference call. “This includes a possible sale, merger, acquisition or in-licensing opportunity."

    | Nov. 4, 2011, 11:36 AM
  • Oct. 21, 2011, 9:59 AM

    Allos Therapeutics (ALTH -6.2%) and AMAG Pharmaceuticals (AMAG +4.5%) terminate their merger agreement after AMAG shareholders fail to approve the issuance of shares of common stock to ALTH stockholders.

    | Oct. 21, 2011, 9:59 AM | 1 Comment
  • Sep. 21, 2011, 9:33 AM

    Allos Therapeutics (ALTH) is up 11%, and AMAG Pharmaceuticals (AMAG) up 2%, after Allos discloses it's received a $2.20/share offer to acquire the company, though it warns its board has not recommended the proposal. AMAG's planned buyout of Allos has been threatened by shareholder opposition following MSMB Capital's offer for AMAG.

    | Sep. 21, 2011, 9:33 AM
  • Sep. 7, 2011, 8:54 AM

    The proposed $686M merger between Amag Pharmaceuticals (AMAG) and Allos Therapeutics (ALTH) could be scuttled after two large shareholders of AMAG threaten to vote against the transaction. Reports say the investors are evaluating if a management shakeup or supporting a tender offer from MSMB Capital might be better options. AMAG +8.1% premarket.

    | Sep. 7, 2011, 8:54 AM
  • Aug. 3, 2011, 8:38 AM

    Amag Pharmaceuticals (AMAG) says it received an unsolicited $381M buyout offer from MSMB Capital Management. The $18/share all-cash offer represents a 25% premium over Tuesday's closing price. A deal would scuttle Amag's planned buyout of Allos Therapeutics (ALTH); Amag shares have lost 25% since the Allos buyout was announced two weeks ago. AMAG +11.2% premarket.

    | Aug. 3, 2011, 8:38 AM
  • Jul. 20, 2011, 8:11 AM

    Allos Therapeutics (ALTH) merges with AMAG Pharmaceuticals (AMAG) in a $686M all-stock deal. The combined firm expects to realize annual cost savings synergies of between $55 million and $60 million, primarily in the first fiscal year after closing. Shares of ALTH +9.2% premarket.

    | Jul. 20, 2011, 8:11 AM